This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $75.75, marking a -0.39% move from the previous day.
CVS Health (CVS) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $75.75, marking a -0.17% move from the previous day.
The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health
Top Research Reports for Home Depot, Toyota & IBM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), Toyota Motor (TM), and International Business Machines (IBM).
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.46, moving +0.53% from the previous trading session.
Magellan (MGLN) Expands in Precision Oncology With Trapelo
by Zacks Equity Research
Magellan Health (MGLN) partners Trapelo Health to offer an all-inclusive approach to value-based care in the innovative arena of precision oncology treatments.
CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide
by Zacks Equity Research
CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $75.04, moving +0.7% from the previous trading session.
Why the Earnings Surprise Streak Could Continue for CVS Health (CVS)
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $76.08, marking a -0.29% move from the previous day.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $73.21, moving +1.82% from the previous trading session.
Why Is CVS Health (CVS) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $74.01 in the latest trading session, marking a -1.41% move from the prior day.
CVS Health (CVS) Extends COVID-19 Testing in Massachusetts
by Zacks Equity Research
CVS Heath's (CVS) antibody testing to be available in nearly 60 MinuteClinic locations and cost $38.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $72.35, marking a -0.48% move from the previous day.
Zacks Industry Outlook Highlights: CVS Health, Walgreen Boots, Herbalife, Rite Aid and Amazon
by Zacks Equity Research
Zacks Industry Outlook Highlights: CVS Health, Walgreen Boots, Herbalife, Rite Aid and Amazon
Magellan's (MGLN) Q4 Earnings Miss Estimates, Decline Y/Y
by Zacks Equity Research
Magellan Health's (MGLN) results reflect a decline in earnings and revenues due to lower contribution from Healthcare and Pharmacy Management units.
3 Pharmacies & Drugstore Stocks to Watch Amid COVID-19 Resurgence
by Urmimala Biswas
Despite severe COVID-19 challenges, higher demand for telemedicine and federal collaborations for vaccine rollout are likely to lend support to the Zacks Retail - Pharmacies and Drug Stores industry. HLF is well positioned to gain now while CVS and RAD hold huge prospects.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Walmart, Home Depot, CVS Health and Booking Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Walmart, Home Depot, CVS Health and Booking Holdings
Top Research Reports for Berkshire Hathaway, Walmart & Home Depot
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Walmart (WMT) and Home Depot (HD).
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
Magellan Health (MGLN), Wellth Tie Up on Behavioral Change
by Zacks Equity Research
Magellan Health (MGLN) initiates a pilot program with Wellth to improve medication adherence and the general health of its members.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $73.49, moving +0.7% from the previous trading session.
CVS Health (CVS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.